Cancer treatment utilizing SP-141 to bind with MDM2 and act as an inhibitor of MDM2 expression
US10472355B2 · kind B2 · utility
0Cited by
1References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 2015 |
| Grant date | Nov 12, 2019 |
| Priority date | — |
| Expiry date | Sep 25, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
An SP-141 compound is a novel small molecule that can serve as a molecular-targeted chemotherapeutic agent. In one embodiment, the labeled compound can comprise SP-141, which comprises 6-methoxy-1-(naphthalen-1-yl)-9 H-pyrido[3,4-b]indote. The compound inhibits expression of oncogenes such as the Mouse Double Minute 2 protein. The compound can bind directly to Mouse Double Minute 2 to inhibit cancer growth including breast cancer growth.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.